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Abstract
Hyperpolarized 13C labelled molecular probes have been used to investigate metabolic pathways of
interest as well as facilitate in vivo spectroscopic imaging by taking advantage of the dramatic signal
enhancement provided by DNP. Due to the limited lifetime of the hyperpolarized nucleus, with signal
decay dependant on T1 relaxation, carboxylate carbons have been the primary targets for development
of hyperpolarized metabolic probes. The use of these carbon nuclei makes it difficult to investigate
upstream glycolytic processes, which have been related to both cancer metabolism as well as other
metabolic abnormalities, such as fatty liver disease and diabetes. Glucose carbons have very short
T1s (< 1 sec) and therefore cannot be used as an in vivo hyperpolarized metabolic probe of glycolysis.
However, the pentose analogue fructose can also enter glycolysis through its phosphorylation by
hexokinase and yield complimentary information. The C2 of fructose is a hemiketal that has a
relatively longer relaxation time (≈ 16 s at 37° C) and high solution state polarization (≈ 12%).
Hyperpolarized [2-13C]-fructose was also injected into a transgenic model of prostate cancer
(TRAMP) and demonstrated difference in uptake and metabolism in regions of tumor relative to
surrounding tissue. Thus, this study demonstrates the first hyperpolarization of a carbohydrate carbon
with a sufficient T1 and solution state polarization for ex vivo spectroscopy and in vivo spectroscopic
imaging studies.
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INTRODUCTION
Recent development of techniques to retain highly polarized spins in solution via dynamic
nuclear polarization (DNP) has enabled hyperpolarized 13C NMR spectroscopy and MR
spectroscopic imaging studies with signal enhancements of over 10,000 fold in short
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acquisition times 1,2. This new technique has powerful applications for metabolic imaging of
cancer. The in-vivo metabolism of [1-13C]-pyruvate and its metabolic products, [1-13C]-lactate,
[1-13C]-alanine and [13C] bicarbonate, have been shown to correlate with disease progression
3 and response to therapy 4 in animal models. DNP substrates require a long T1 relaxation to
facilitate efficient spin diffusion during the process of hyperpolarization 5,6. Carbonyl carbons,
which lack attached protons and limit the relaxation as a result of dipolar cross relaxation, have
been the standard species to label and polarize with T1’s on the order of 40–60 seconds,
depending on the field strength 7–9.
Although a number of molecules of interest have been polarized and observed through their
carbonyl carbons 1,3,9–11, a great number of important metabolic intermediates do not contain
a carbonyl. Specifically, changes in carbohydrate metabolism occur with the evolution and
progression of cancer 12–14 as well as a number of other human diseases such as non-alcoholic
fatty liver disease 15–17. Glucose carbons have very short T1s (< 1 sec) and therefore
uniformly 13C labelled glucose, a mainstay of current metabolic studies 18,19, cannot be used
as an in vivo hyperpolarized metabolic probe of glycolysis.
Fructose, occurring as an isomeric mixture of five and six membered rings, has as its most
stable isomer β-fructopyranose with a hemiketal in the C2 position. Fructose can enter glycolyis
via hexokinase or fructokinase 20–24. The one-step metabolism via hexokinase to the
phosphorylated fructose-6-phosphate is analogous to the first step of glycolysis, in which
glucose is phosphorylated to glucose-6-phosphate. The metabolic flux to fructose-6-phosphate
in the cell is related to the downstream glycolytic metabolic events as well as activity of the
pentose phosphate pathway (PPP) 25–27. The pentose phosphate pathway is responsible for the
predominant amount of nucleotide synthesis (which is increased at high turnover rates) and
has been postulated to be a source of regeneration of NADPH in cancer cells 14 making them
more resistant to oxidative stress and allowing them to replenish glutathione.
Furthermore, metabolism of fructose is implicated in non-alcoholic steatohepatitis (NASH)
15, and in the pathogenesis of specific types of cancer. Fructose can also be metabolized to the
fructose-1-phosphate via fructokinase, a reaction that takes place primarily in the liver 20.
Hepatic uptake is via the GLUT5 transporter, that demonstrates relative specificity for fructose.
Expression of this transporter may be an important biomarker for disease in extrahepatic
tissues. For example, the human fructose transporter, GLUT5 (as shown in Figure 1), is highly
expressed in breast cancer cell lines but not by normal breast tissue 28. A recent study of
metabolites in the prostate gland has also shown a relationship between fructose and benign
versus cancer tissues 29. Thus the goal of this study was to investigate a new non-carbonyl
hyperpolarized 13C probe, [2-13C]-fructose for the study of metabolism in vivo.
MATERIALS AND METHODS
Hyperpolarized [2-13C]-Fructose
A 4.0M solution of [2-13C]-fructose (Isotec, Miamisburg, OH) in water containing 15mM
OX063 trityl radical (Oxford Instruments) was hyperpolarized on a Hypersense instrument
(Oxford Instruments) as previously described 1. The frozen sample was dissolved in 1X
phosphate buffered saline (PBS), with a resultant pH of 7.6, and transferred immediately to a
10mm NMR tube.
11.7T NMR Studies
NMR studies were performed on an 11.7T Varian INOVA spectrometer (125MHz 13C, Varian
Instruments) using a 10mm 15N/31P/13C broadband direct detect probe and temperature
controlled at 37°C. Initially, a thermal spectrum was acquired for a natural abundance fructose
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sample in 1X PBS buffer at 37°C (nt=9000, sw=30000, np=30000, TR=3.5s, acq time= 0.5s)
using a 45-degree pulse. Figure 2 demonstrates the natural abundance 13C spectrum of fructose.
The C2 carbon resonances are denoted by the blue brackets and correspond to the isomeric
distribution of the two ring forms (pyranose and furanose forms) of the fructose molecule. For
the acquisition of hyperpolarized 13C spectra eighty pulse and acquire hyperpolarized 13C
NMR spectra (1 scan, spectral window = 20000 Hz, number of points= 40000, TR=3s, total
acquisition time = 2 min 55s) were acquired using a 5° pulse and proton decoupled using a
waltz-16 decoupling scheme. Hyperpolarized studies were followed by acquisition of thermal
data with nearly identical parameters, using a 90° flip angle and a repetition time of greater
than four T1’s (TR=300s, nt=16). For T1 measurements hyperpolarized solution was placed
into a NMR tube pre-heated to 37° C and this temperature is maintained using the variable
temperature unit of the NMR spectrometer. T1’s were determined by collecting a series of
spectra with 3 sec temporal resolution, starting 12 secs after dissolution. These spectra were
then fit to a mono-exponential function to determine the spin-lattice relaxation time as
previously described9,30,31. Percent polarization in solution was calculated by comparing the
first hyperpolarized spectrum acquired with its thermal spectrum, correcting for differences in
tip angle (5 versus 90), and the number of transients (1 versus 16) obtained. Solution state
polarizations were calculated by correcting the enhancement for the T1 relaxation during the
transfer time (12 secs) from the polarizer to the spectrometer, and the thermal polarization at
11.7T (9.6 ppm).
For NMR studies of the enzymatic conversion of Fructose to fructose-6-phosphate,
hyperpolarized [2-13C]-fructose was reacted with 400U of hexokinase (Sigma Aldrich) in the
presence of 15mM ATP, 50mM TRIS and 13mM MgCl2. The labelling and mechanism for
transport and metabolism is shown below (Figure 1), though in this enzymatic study the
transport element has been removed and the enzyme activity was independently measured.
Peaks corresponding to fructose-6-phosphate were identified using a natural abundance carbon
spectrum, using a similar set of experimental parameters.
3T Studies
T1 studies were performed using a 3T GE Signa™ scanner (GE Healthcare, Waukesha, WI)
equipped with the MNS (multinuclear spectroscopy) hardware package similar to studies at
11.7T, with temperature maintained using a heating pad calibrated to 37°C. Solution spectra
were acquired using a 5° non-localized pulse, TR=3s and fit to a mono-exponential. The RF
coil used in these experiments was a dual-tuned 1H-13C coil with a quadrature 13C channel and
linear 1H channel construction based on an earlier design and also used in 13C-pyruvate mouse
imaging studies. For animal studies, T2-weighted fast spin echo images were acquired prior to
MRSI studies to denote anatomy and place voxels on the region of interest. In vivo MRSI
studies were carried out using a compressed sensing double spin 3D MRSI acquisition scheme
as previously published 32 with a TE = 140 ms, TR=215 ms, FOV = 8 cm × 8 cm, and 16 × 8
resolution. 500 μl of of 80 mM [2-13C]-fructose (0.0013 mmols/kg) was injected similar to
previously described methods for [1-13C] pyruvate in a transgenic model of prostate cancer
(TRAMP) 3. High dose infusions of fructose (0.5g/kg) can lead to hyperuricemia33, but this is
well above the dose given in these studies (0.24mg/kg). These injections were compared to the
standard [1-13C]-pyruvate injection for the same voxel in a tumor region of interest. Maps of
resonance distributions were generated from the peak heights in each voxel and overlaid on
the corresponding T2-weighted image.
RESULTS AND DISCUSSION
Calculated T1’s for the C2 fructose carbon are tabulated in Table 1 for the cyclic isomers of
fructose (β-fructofuranose, β-fructopyranose, α-fructofuranose) at both 11.7T and 3T, the field
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stenghts of the ex vivo and in vivo hyperpolarized studies. The open chain (linear) isomer of
fructose is present in very small amounts (0.4%) 21,34 and not observed in the hyperpolarized
NMR spectra. There was no significant difference in the C2 T1 between the cyclic isomers of
fructose, most likely due to the fast chemical of the isomeric forms 34. There was a small
decrease in T1 relaxation (≈ 2 sec) of the C2 carbon with decreasing magnetic field strength
from 11.7T to 3T (Table 1). To date, hyperpolarized 13C agents have involved labelling at
carbonyl positions, such as the C1 position of pyruvate, due to their relatively long T1’s 1,2,7,
9,30,35. In contrast to the quaternary hemiketal carbon of the fructose isomers, carbonyl carbons
decrease in T1 with increasing field strengths36. This difference is predominantly due to
chemical shift anisotropy dominating the T1 relaxation of carbonyl carbons at higher field
strengths36. This does not hold for the hemiketal of fructose, leading to the typical lengthening
of T1 with increasing field strength. Percent polarizations (Table 1) show similar values for
the isomers of fructose with an average solution state polarization at 37° C of 12%. These
polarization values are comparable, although somewhat lower, than those reported for other
compounds of interest1,37,38 such as pyruvate which has been reported to be polarized from
21–30%3,39. There was no T1 dependence on pH observed for pH ranges 5.9–7.8 for the
fructose isomers.
The polarization levels were calculated relative to thermal signals from the same sample. The
DNP polarizer sits in the fringe field of the 11.7T spectrometer in order to eliminate the
possibility of passing the hyperpolarized sample through a zero field and loosing all
polarization. For carbonyls such as the C1 of pyruvate, we know that the T1 at lower magnetic
field strengths, and that the T1 in the fringe field of the magnet should be longer, on the order
of 80 secs as compared to 52 secs at 11.7T. This is due to the relationship between CSA and
field strength (CSA1B0 2), which dominates the carbonyl T1 at high field strengths 36. However,
as demonstrated in this publication, the T1 of the quaternary C2 carbon of fructose is only
slightly longer at higher field strengths (Table 1). Therefore the T1 in the fringe field should
be slightly shorter than 3T, which would result in a small underestimation of the % polarization
at time zero.
The reaction of hyperpolarized C2-fructose with hexokinase after addition of fructose to the
hexokinase in buffer within the NMR yields the phosphorylated pentose within 5 seconds
(Figure 3). An expansion of the downfield region of the spectrum (Figure 3a) shows the split
in the 105.5ppm resonance, which is a combination of both the β-fructofuranose and the β-
fructofuranose-6-phosphate (the predominant isomeric form of fructose-6-phosphate). Figure
3 also compares the first scan of the hyperpolarized acquisition (Figure 3b) versus the thermal
spectrum acquired over 85 minutes post DNP (Figure 3c). It is apparent that the enzyme has
now fully converted the fructose to fructose-6-phosphate and there is no longer a resonance
corresponding to β-fructopyranose.
Figure 4 demonstrates the metabolism following separate injections of 80mM hyperpolarized
fructose (Figure 4d) and pyruvate (Figure 4e) in the same TRAMP mouse. As previously
published (3), the primary TRAMP tumor demonstrates high levels of hyperpolarized lactate,
as well good signal to noise spectra of hyperpolarized fructose and it’s metabolite β-
fructofuranose-6-phosphate. Injections of 80mM hyperpolarized fructose yielded an average
total signal-to-noise ratio of 21.0 ± 2.1 in tumor slices (an average of 70 voxels in 2 slices was
used for N=3 TRAMP mice). Because the isomeric ratio of the fructose pyranose to furanose
in solution is approximately 77/23 21 the in vivo peak at 105.5ppm (and if visible the
downstream 108.25ppm resonance) is not solely due to β-fructofuranose-6-phosphate but also
has a small contribution from β-fructofuranose. In this relatively large TRAMP tumor, both
high levels of LDH activity and hexokinase activity were observed 15 secs post-injection in
the same 0.035cc voxels. Figure 4b demonstrates the distribution of the total fructose signal
throughout the slice, a measure of combined delivery and uptake of hyperpolarized Fructose.
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Slightly higher levels of total hyperpolarized fructose were observed in the tumor region
relative to surrounding muscle in the same slice. In comparison, Figure 4c demonstrates the
distribution of the resonance at 105.5ppm, which includes the metabolite β-fructofuranose-6-
phosphate. Importantly, this resonance has a good signal-to- noise (≈ 5:1) and is co-localized
in regions of high lactate within the tumor (Figures 4d and 4e).
Figure 5 demonstrates a case where there was tumor only in the left side of the murine prostate,
providing a direct comparison of hyperpolarized fructose uptake/delivery and metabolism
between benign and malignant prostate tissues. The MRSI data demonstrated that the resonance
corresponding to the composite β-fructofuranose and β-fructofuranose-6-phosphate were
higher in the regions of tumor as compared to the benign prostate tissues (Figure 5d).
Interestingly, there is no difference in total hyperpolarized fructose in regions of malignant
versus benign prostate tissue. However, the composite β-fructofuranose and β-
fructofuranose-6-phosphate resonance (Figure 5c) was higher in malignant left lobe of the
prostate as compared to the benign right side (Figure 5c and d).
CONCLUSION
In this study, [2-13C]-fructose was hyperpolarized using the DNP method and shown to have
sufficiently long T1’s and polarizations sufficient for hyperpolarized 13C NMR spectroscopic
and MRSI studies. The hemiketal C2 of fructose demonstrates the first non-carbonyl to be
hyperpolarized for use as a metabolic probe and suggests the potential of using other
hyperpolarized probes involving quaternary carbons even those in ring structure. Enzymatic
conversion of hyperpolarized [2-13C]-fructose, to fructose-6-phosphate has been demonstrated
in vitro and in vivo. While the composite β-fructofuranose and β-fructofuranose-6-phosphate
resonance was associated with tumor regions, it was also present in some surrounding benign
tissues, and additional studies are necessary to fully understand the composition of this
resonance and its relationship to malignancy. The enzymatic conversion of hyperpolarized
fructose allows the probing of important changes in glycolytic metabolism upstream of
pyruvate, including upregulated hexose uptake 28, hexokinase activity and changes in flux
through the pentose phosphate pathway 14. Although, this study was focused on prostate cancer
models, upstream glyolytic processes have been the basis of a number of cancer studies
including the HIF-1 and PI3K related processes 14. Therefore changes in fructose metabolism
may be important in the assessment of therapies that target these pathways. A potential link
between fructose metabolism and non-alcoholic fatty liver disease has also been demonstrated
40 and thus hyperpolarized fructose could become a valuable metabolic imaging agent to study
this and other diseases both ex vivo and in vivo. Moreover, the dose of fructose given in this
murine study translates into a very safe patient dose.
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Refer to Web version on PubMed Central for supplementary material.
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The mechanism for transport by GLUT5 and the first step of metabolism of fructose to
fructofuranose-6-phosphate by hexokinase.
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The natural abundance spectrum of fructose (a) and DNP spectrum of [2-13C]-fructose (b).
The linear form is present in the DNP spectrum, but at a very low level analogous to the thermal
spectrum. (Top) Structures of each of the isomers are shown with their analogous resonance.
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(a) Spectrum of fructose reacted with 400U of hexokinase, the zoomed in region demonstrates
the resonances corresponding to the fructose and fructose-6-phosphate. (b) The dynamic
spectrum after 5 secs of reaction with hexokinase. (c) The thermal spectrum of same solution
with hexokinase averaged 85 min post DNP.
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(a) T2-weighted image of a moderate to late stage TRAMP mouse prostate tumor. Metabolite
image overlays of the resonances corresponding to total hyperpolarized fructose (b) and
composite β-fructofuranose-6-phosphate and β-fructofuranose (c) obtained after injection of
80mM [2-13C] fructose demonstrate spatial differences in total fructose versus the composite
β-fructofuranose-6-phosphate resonance. Spectra corresponding to the two red voxels (d) in
the tumor demonstrate the resonances corresponding to β-fructopyranose and the composite
β-fructofuranose-6-phosphate and β-fructofuranose. Pyruvate and lactate resonances are
shown from the same locations (e) obtained after an injection of 80mM hyperpolarized
pyruvate in the same mouse.
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(a) T2-weighted image of a TRAMP mouse with tumor only on the right side of the prostate.
Metabolic images of total hyperpolarized [2-13C] fructose resonances (b) and the composite
β-fructofuranose-6-phosphate and β-fructofuranose (c) are shown overlaid on the T2 weighted
image. Resonances corresponding to the β-fructopyranose and composite β-fructofuranose-6-
phosphate and β-fructofuranose are shown in the corresponding spectral array (d). The yellow
area demonstrates a region of tumor, compared to a region of benign prostate tissue in red. An
unassigned spurious, low signal-to-noise resonance appears at 115 ppm.
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T1 relaxation times at 11.7T and 3T (N=3 for both, ± s.d.) are shown for each of the isomers
as well as percent polarization (N=3), which have been corrected for the time from dissolution
to measurement. All studies were conducted at 37°C.
Isomer T1 sec (11.7T) T1 sec (3T) %pol
β-fructopyranose 16.3 ± 0.5 14.5 ± 0.3 12.0 ± 2.2
β-fructofuranose 15.8 ± 0.5 13.4 ± 0.5 11.6 ± 2.5
α-fructofuranose 15.8 ± 0.5 13.4 ± 0.4 11.8 ± 2.0
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